Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Cohn, DE, Havrilesky, LJ, Osann, K, Lipscomb, J, Hsieh, S, Walker, JL, Wright, AA, Alvarez, RD, Karlan, BY, Bristow, RE, DiSilvestro, PA, Wakabayashi, MT, Morgan, R, Mukamel, DB, and Wenzel, L. "Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice." Gynecologic oncology 138, no. 3 (September 2015): 712-716.

Full Text

Dottino, JA, Cliby, WA, Myers, ER, Bristow, RE, and Havrilesky, LJ. "Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention." Gynecologic oncology 138, no. 3 (September 2015): 694-699.

Full Text

Turner, TB, Habib, AS, Broadwater, G, Valea, FA, Fleming, ND, Ehrisman, JA, Di Santo, N, and Havrilesky, LJ. "Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging." Journal of minimally invasive gynecology 22, no. 6 (September 2015): 1004-1010.

Full Text

Zhang, C, Roque, D, Ehrisman, JA, DiSanto, N, Broadwater, G, Doll, KM, Gehrig, PA, Secord, AA, and Havrilesky, LJ. "Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer." Gynecologic Oncology Reports 13 (August 2015): 49-52.

Full Text

Brooks, SE, Carter, RL, Plaxe, SC, Basen-Engquist, KM, Rodriguez, M, Kauderer, J, Walker, JL, Myers, TKN, Drake, JG, Havrilesky, LJ, Van Le, L, Landrum, LM, and Brown, CL. "Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study." Gynecologic oncology 138, no. 1 (July 2015): 101-108.

Full Text

Phippen, N, Havrilesky, L, Barnett, J, Hamilton, C, Stany, M, and Lowery, W. "Abstract 10: Does routine post-treatment PET/CT add value to the care of women with locally advanced cervical cancer?." Gynecologic Oncology 137, no. 3 (June 2015): 594-595.

Full Text

Secord, AA, Coleman, RL, Havrilesky, LJ, Abernethy, AP, Samsa, GP, and Cella, D. "Patient-reported outcomes as end points and outcome indicators in solid tumours." Nature Reviews. Clinical Oncology 12, no. 6 (June 2015): 358-370. (Review)

Full Text

Kushnir, CL, Angarita, AM, Havrilesky, LJ, Thompson, S, Spahlinger, D, Sinno, AK, Tanner, EJ, Secord, AA, Roche, KL, Stone, RL, and Fader, AN. "Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)." Gynecologic oncology 137, no. 3 (June 2015): 503-507.

Full Text

Forde, B, Wallbillich, J, Havrilesky, LJ, and Cohn, DE. "A personalized paradigm in the treatment of platinum-resistant ovarian cancer: A cost utility analysis of genomic-based versus cytotoxic therapy." April 2015.

Full Text

Miller, CR, Chappell, NP, Leath, CA, Phippen, NT, Havrilesky, LJ, and Barnett, JC. "Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?." April 2015.

Full Text

Pages